(Q44396463)

2 December 2017

title

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes (English)

1 reference

2 December 2017

5

1 reference

2 December 2017

7

1 reference

2 December 2017

Umit Yasar

2

0 references

author name string

Laimonas Griskevicius

1

1 reference

2 December 2017

Mia Sandberg

3

1 reference

2 December 2017

Mats Hidestrand

4

1 reference

2 December 2017

Gunnel Tybring

6

1 reference

2 December 2017

Marja-Liisa Dahl

8

1 reference

2 December 2017

publication date

9 April 2003

1 reference

European Journal of Clinical Pharmacology

2 December 2017

published in

1 reference

2 December 2017

volume

59

1 reference

2 December 2017

issue

2

1 reference

2 December 2017

page(s)

103-109

1 reference

Metabolism and pharmacokinetics of oxazaphosphorines

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0590-6

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0590-6

Pharmacogenetics and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0590-6

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0590-6

Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0590-6

Biochemistry and molecular biology of the human CYP2C subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0590-6

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0590-6

Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0590-6

Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0590-6

Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0590-6

Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0590-6

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0590-6

Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0590-6

The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0590-6

The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma

21 January 2018

1 reference

12 December 2020

Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles

1 reference

12 December 2020

Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

1 reference

12 December 2020

The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity

1 reference

12 December 2020

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism

1 reference

12 December 2020

Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

1 reference

12 December 2020

Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.

1 reference

12 December 2020

Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor

1 reference

12 December 2020

Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype

1 reference

12 December 2020

Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects

1 reference

12 December 2020

Role of CYP2C9 polymorphism in losartan oxidation

1 reference

12 December 2020

Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients

1 reference

12 December 2020

Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture

1 reference

12 December 2020

Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation

1 reference

12 December 2020

Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation

1 reference

12 December 2020

Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes

1 reference

12 December 2020

Clinical pharmacokinetics of cyclophosphamide

1 reference

12 December 2020

A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function.

1 reference

12 December 2020

Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes

1 reference

12 December 2020

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

12 December 2020

Implications of polymorphic cytochrome p450-dependent drug metabolism for drug development

1 reference

12 December 2020

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans

1 reference

12 December 2020

Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes

1 reference

12 December 2020

10.1007/S00228-003-0590-6

Identifiers

DOI

1 reference

2 December 2017

1 reference